TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Beta Cell Restoration Through Fat Mitigation
Brief Summary: Weight loss achieved through gastric banding will be superior to treatment with metformin in preserving or restoring pancreatic beta cell function in people with prediabetes or mild type 2 diabetes.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin Comparator | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Metformin Comparator; Assigned to Arm(s): Metformin
C: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: gastric banding; Type: EXPERIMENTAL; Interventions: Device: gastric banding | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DEVICE; Name: gastric banding; Assigned to Arm(s): gastric banding
D: Arm Label: 3.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 2.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 1.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.25 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Placebo solution, Drug: Metformin | Arm Label: Placebo/Sitagliptin (Baseline Through 104 Weeks); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo solution, Drug: Placebo tablet, Drug: Metformin | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265 | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo solution; Assigned to Arm(s): Placebo/Sitagliptin (Baseline Through 104 Weeks), Sitagliptin | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265, Placebo/Sitagliptin (Baseline Through 104 Weeks) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265, Placebo/Sitagliptin (Baseline Through 104 Weeks), Sitagliptin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Beta Cell Restoration Through Fat Mitigation
Brief Summary: Weight loss achieved through gastric banding will be superior to treatment with metformin in preserving or restoring pancreatic beta cell function in people with prediabetes or mild type 2 diabetes.


Options:
A: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: gastric banding; Type: EXPERIMENTAL; Interventions: Device: gastric banding | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DEVICE; Name: gastric banding; Assigned to Arm(s): gastric banding
B: Arm Label: Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Alogliptin; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Alogliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of the Efficacy of Electrical Pudendal Nerve Stimulation to Pelvic Floor Muscle Training With Transvaginal Electrical Stimulation in Treating Female Stress Incontinence
Brief Summary: The purpose of this study is to determine whether electrical pudendal nerve stimulation is more effective than pelvic floor muscle training with Transvaginal electrical stimulation in treating female stress incontinence.


Options:
A: Arm Label: Electrical pudendal nerve stimulation; Type: EXPERIMENTAL; Interventions: Behavioral: Electrical pudendal nerve stimulation | Arm Label: PFM training with Transvaginal ES; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PFM training, Behavioral: Transvaginal ES | Intervention Type: BEHAVIORAL; Name: Electrical pudendal nerve stimulation; Assigned to Arm(s): Electrical pudendal nerve stimulation | Intervention Type: BEHAVIORAL; Name: PFM training; Assigned to Arm(s): PFM training with Transvaginal ES | Intervention Type: BEHAVIORAL; Name: Transvaginal ES; Assigned to Arm(s): PFM training with Transvaginal ES
B: Arm Label: Electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: Electroacupuncture | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham Electroacupuncture | Arm Label: Solifenacin Succinate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin Succinate | Intervention Type: DEVICE; Name: Electroacupuncture; Assigned to Arm(s): Electroacupuncture group | Intervention Type: DEVICE; Name: Sham Electroacupuncture; Assigned to Arm(s): Placebo group | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate group
C: Arm Label: electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: electroacupuncture group | Arm Label: sham electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: sham electroacupuncture group | Intervention Type: DEVICE; Name: electroacupuncture group; Assigned to Arm(s): electroacupuncture group | Intervention Type: DEVICE; Name: sham electroacupuncture group; Assigned to Arm(s): sham electroacupuncture group
D: Arm Label: acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: acupuncture | Arm Label: Solifenacin plus PFMT; Type: ACTIVE_COMPARATOR; Interventions: Drug: solifenacin, Procedure: PFMT | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): acupuncture | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin plus PFMT | Intervention Type: PROCEDURE; Name: PFMT; Assigned to Arm(s): Solifenacin plus PFMT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mesenchymal Stromal Cells (MSC) for the Treatment of Severe (Grade II-IV) Steroid-resistant Graft Versus Host Disease (GVHD): a Phase I Trial
Brief Summary: This is a bicentric, prospective, non randomized study. Pediatric and adult patients will be treated.

Rationale: MSC have shown promising effects by reversal of severe therapy-resistant acute GvHD. As a common therapeutic line of action is not shared for steroid resistant GVHD, it is important to establish the toxicity and the feasibility of preparation and infusion of third party MSCs for acute steroid resistant GVHD and acute phases of chronic steroid resistant GVHD.

A total of 10 patients (pediatric and adults) need to be enrolled in the study. Patients who present clinical signs of either acute or chronic steroid resistant GVHD will receive by intravenous infusion at least two fixed doses of mesenchymal stem cells with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor) regardless of the rate of HLA mismatch.

Primary objectives are to establish the feasibility and the toxicity of preparation and infusions of third party MSCs for the treatment of steroid resistant acute and acute phases of chronic grade II-IV GVHD.

Secondary objectives are:

1. To document the efficacy of MSC infusion in steroid resistant acute and acute phases of chronic GVHD grade II-IV.
2. To document the rate of GVHD recurrence in MSCs infused patients.
3. To document relapse of hematological malignancies post MSC infusions in patients undergoing MSCs treatment for steroid refractory GvHD.
4. To document the overall survival of MSC infused patients for steroid refractory GvHD.


Options:
A: Arm Label: Mesenchymal Stromal Cells (MSC); Type: EXPERIMENTAL; Interventions: Genetic: Mesenchymal stromal cells | Intervention Type: GENETIC; Name: Mesenchymal stromal cells; Assigned to Arm(s): Mesenchymal Stromal Cells (MSC)
B: Intervention Type: PROCEDURE; Name: Mesenchymal stem cell (MSC); Assigned to Arm(s): N/A
C: Arm Label: Auto-hMSCs; Type: EXPERIMENTAL; Interventions: Biological: Auto-hMSCs | Arm Label: Allo-hMSCs; Type: EXPERIMENTAL; Interventions: Biological: Allo-hMSCs | Intervention Type: BIOLOGICAL; Name: Auto-hMSCs; Assigned to Arm(s): Auto-hMSCs | Intervention Type: BIOLOGICAL; Name: Allo-hMSCs; Assigned to Arm(s): Allo-hMSCs
D: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Brief Summary: The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Other: Standard of care | Arm Label: Evolocumab + SOC; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + SOC, Standard of Care | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of Care
C: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Brief Summary: The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.


Options:
A: Arm Label: alirocumab SAR236553 (REGN727) - Dose A; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Arm Label: alirocumab SAR236553 (REGN727) - Dose B; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Arm Label: alirocumab SAR236553 (REGN727) - Dose C; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Intervention Type: DRUG; Name: alirocumab SAR236553 (REGN727); Assigned to Arm(s): alirocumab SAR236553 (REGN727) - Dose A, alirocumab SAR236553 (REGN727) - Dose B, alirocumab SAR236553 (REGN727) - Dose C
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo
D: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Brief Summary: The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 28 Days on/off (Placebo 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14)
C: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
D: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Brief Summary: The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.


Options:
A: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
B: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 28 Days on/off (Placebo 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14)
C: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)
D: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of No-Calorie Sweetened Beverages Within a Weight Loss Behavior Change Program and During Subsequent Weight Maintenance
Brief Summary: The no calorie drink study is looking for over 300 people to participate. The study is evaluating the effect of no calorie beverages on weight loss and weight maintained over time in people who drink diet beverages every day as compared to water only drinkers during the 1 year study period.


Options:
A: Intervention Type: BEHAVIORAL; Name: Promotion of a healthy diet and physical activity; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Avoidance of Alcohol, Drugs, and Tobacco; Assigned to Arm(s): N/A
B: Arm Label: Low intensity arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary, physical activity and sleeping | Arm Label: High intensity arm; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary, physical activity and sleeping | Intervention Type: BEHAVIORAL; Name: Dietary, physical activity and sleeping; Assigned to Arm(s): High intensity arm, Low intensity arm
C: Arm Label: No calorie beverages; Type: EXPERIMENTAL; Interventions: Behavioral: 2 no calorie beverages per day | Arm Label: Water; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 water beverages per day | Intervention Type: BEHAVIORAL; Name: 2 no calorie beverages per day; Assigned to Arm(s): No calorie beverages | Intervention Type: BEHAVIORAL; Name: 2 water beverages per day; Assigned to Arm(s): Water
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sugar-sweetened beverage consumption | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sugar-sweetened beverage consumption; Assigned to Arm(s): 1

Answer: C